The status of SGLT2 inhibitors in the current EASD/ADA 2022 therapeutic recommendations for the treatment of type 2 diabetes mellitus and their use in practice: case reports and commentary
Authors:
Emil Martinka 1; Viera Šuličová 2; Gabriela Švrčková 3; Martina Barátová 4
Authors‘ workplace:
Národný endokrinologický a diabetologický ústav, n. o., Ľubochňa
1; Nemocnica AGEL Handlová s. r. o.
2; DIAMEDICAL, s. r. o., Skalica
3; Nemocničná a. s., Malacky
4
Published in:
Forum Diab 2022; 11(3): 165-170
Category:
Case Reports
Overview
In this work, we comment on the position of SGLT2 cotransport inhibitors (SGLT2i) in the current EASD/ADA 2022 therapeutic recommendation for the treatment of type 2 diabetes mellitus. At the same time, we compare them with current treatment options using SGLT2i in Slovakia. We also comment on the use of SGLT2i in practice by analyzing and commenting on 3 case reports from outpatient practice.
Keywords:
case reports – EASD/ADA 2022 recommendations – SGLT2-inhibitors
Sources
1. Davies MJ, Vanita R, Aroda et al. [ADA/EASD konsenzus 2022]. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2022; 45(11): 2753–2786. Dostupné z DOI: <https://doi.org/10.2337/dci22–0034>.
2. Martinka E, Mokáň M, Tkáč I et al. Interdisciplinárne odporúčania pre diagnostiku a liečbu diabetes mellitus, jeho komplikácií a najvýznamnejších sprievodných ochorení – 2021. Forum Diab 2021; 10(Suppl 2). Dostupné z WWW: <https://www.forumdiabetologicum. sk/casopisy/forum-diabetologicum/archiv-cisel/2021-supplementum-2–2>.
3. Zinman B, Wanner C, Lachin JM et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373(22): 2117–2128. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1504720>.
4. Neal B, Perkovic V, Mahaffey KW et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377(7): 644–657. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1611925>.
5. Wiviott, SD, Raz, I, Bonaca, MP et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2019;380(4): 347–357. Dostupné z DOI: <https://doi.org/10.1056/NEJMoa1812389>.
6. Packer M, Anker SD, Butler J et al.[EMPEROR-Reduced Trial Investigators]. Cardiovascular and Renal Outcomes With Empagliflozin in Heart Failure. N Engl J Med 2020; 383(15): 1413–1424. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2022190>.
7. Anker SD, Butler J, Filippatos G et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction N Engl J Med 2021; 385(10): 1451–1461. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2107038>.
8. Jardiance®. Súhrn charakteristických vlastností lieku. ŠÚKL, marec 2022. Dostupné z WWW: <https://www.ema.europa.eu/en/documents/product-information/jardiance-epar-product-information_sk.pdf>.
9. Wanner C, Inzucchi SE, Lachin JM et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016; 375(4): 323–234. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1515920>.
10. Perkovic V, Jardine MJ, Neal B et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380(24): 2295–2306. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1811744>.
11. Heerspink HJ, Stefánsson BV, CorreaRotter R et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020; 383(15): 1436–1446. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2024816>.
12. Chehrehgosha H, Sohrabi MR, Ismail-Beigi F et al. Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Diabetes Ther 2021; 12(3): 843–861. Dostupné z DOI: <http://dx.doi.org/10.1007/s13300–021–01011–3>.
13. MZSR. Zoznam kategorizovaných liekov 1.12.2022 – 31.12.2022 – INFORMATÍVNY MATERIÁL. Časť B. Indikačné obmedzenia. Dostupné z WWW: <https://www.health.gov.sk/Clanok?lieky202212>.
14. Jardiance. Súhrn údajov o prípravku. EMA. Dostupné z WWW: <https://www.ema.europa.eu/en/medicines/human/EPAR/jardiance>.
15. Forxiga. Súhrn údajov o prípravku. EMA. Dostupné z WWW: <https://www.ema.europa.eu/en/medicines/human/EPAR/forxiga>.
16. Herrington WH, Staplin N, Wanner C et al. [EMPA-KIDNEY Collaborative Group]. Empagliflozin in Patients with Chronic Kidney Disease. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2204233>.
17. Cosentino F, Grant PJ, Aboyans V et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2020; 41(2): 255–323. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehz486>.
18. Patorno E, Pawar A, Franklin JM et al. Empagliflozin and the risk of heart failure hospitalization in routine clinical care. Circulation. 2019; 139(25): 2822–2830. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.118.039177>.
19. Zelniker TA, Wiviott SD, Raz I et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019; 393(10166): 31–39. Dostupné z DOI: https://doi.org/10.1016/S0140–6736(18)32590-X.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Forum Diabetologicum
2022 Issue 3
Most read in this issue
- New criteria for the diagnosis of gestational diabetes mellitus and their consequences
- The status of SGLT2 inhibitors in the current EASD/ADA 2022 therapeutic recommendations for the treatment of type 2 diabetes mellitus and their use in practice: case reports and commentary
- New trends in current bariatric-metabolic surgery and their contribution to the treatment of (pre)diabetes
- Presence and near future of pharmacological treatment of obesity/diabesity